title: [Tumor inhibiting and immunoloregulation effects of Mylabris Mixture on H22 cancer-bearing mice].
abstract: OBJECTIVE
  To investigate the mechanisms of tumor inhibiting and immunoloregulation of Mylabris Mixture on H22 cancer-bearing mice.
  
  
  METHODS
  H22 cancer-bearing mice were chosen to observe the effects of tumor inhibiting and detect the proliferation function of T lymphocytes, the toxicity function of NK cells, the changes of T lymphocytes and the contents of interferon-gamma and interleukin-4.
  
  
  RESULTS
  Mylabris Mixture could obviously inhibit the growth of H22 cancer in mice, and the tumor inhibition rat was 65.76%. The stimulation index of T lymphocyte transformation and percentage of NK cells in Mylabris Mixture-treated group were obviously higher than those in the normal control group. The subpopulation proportion of T lymphocytes in Mylabris Mixture-treated group was changed more than the normal control group. The production of interferon-gamma and interleukin-4 by T lymphocytes obviously increased in Mylabris Mixture-treated group (P<0.05, P<0.001).
  
  
  CONCLUSIONS
  Mylabris Mixture has the effect of inhibiting the growth of tumor constitution, and regulating immunological function on mice with tumor. Its mechanisms include the reinforcement of T lymphocyte immune function, NK cell killing function and humoral immune function.
authors.affiliation: Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Medical College of Shanghai Jiao Tong University, Shanghai 200011, China. zagssmu@sina.com
authors.forename: A-Gao
authors.initials: AG
authors.lastname: Zhou
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: De-Yun
authors.initials: DY
authors.lastname: Kong
authors.forename: Yin
authors.initials: Y
authors.lastname: Wang
authors.forename: Hui-Zhen
authors.initials: HZ
authors.lastname: Zhang
authors.forename: Shu-Jun
authors.initials: SJ
authors.lastname: Wang
authors.forename: Gang
authors.initials: G
authors.lastname: Kui
authors.forename: Sheng
authors.initials: S
authors.lastname: Hong
authors.forename: Hai-Liang
authors.initials: HL
authors.lastname: Ge
authors.forename: Qiu-Hua
authors.initials: QH
authors.lastname: Ren
authors.forename: Xu-Ming
authors.initials: XM
authors.lastname: Mao
authors.forename: Jia-Rong
authors.initials: JR
authors.lastname: Dong
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D001517:Coleoptera / Q000737:chemistry*; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage; D006801:Humans; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008297:Male; D008419:Materia Medica; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D008419:Materia Medica